NA
CSTL icon

NewEdge Advisors’s Castle Biosciences CSTL Stock Holding History

NewEdge Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Buy
+842
New +$18.8K ﹤0.01% 3358
2025
Q1 		– Sell
-247
Closed -$6.58K – 3997
2024
Q4 		$6.58K Buy
+247
New +$7.52K ﹤0.01% 3157
2024
Q1 		– Sell
-250
Closed -$5.39K – 3852
2023
Q4 		$5.39K Buy
+250
New +$4.4K ﹤0.01% 3103
2023
Q1 		– Sell
-398
Closed -$9.37K – 3562
2022
Q4 		$9.37K Buy
+398
New +$9.23K ﹤0.01% 2393

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's CSTL Position: Q2 2026 in Review

NewEdge Advisors opened a new position in Castle Biosciences (CSTL) in Q2 2026: 842 shares worth $20.1K. The stake represents ﹤0.01% of the portfolio and ranks #3358 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in CSTL as recently as Q4 2024.

NewEdge Advisors first reported a position in CSTL in Q4 2022 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • NewEdge Advisors held 842 shares of Castle Biosciences worth $20.1K as of Q2 2026.
  • Castle Biosciences was a new NewEdge Advisors position in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3358 holding.
  • NewEdge Advisors first reported a position in Castle Biosciences in Q4 2022 and has held it in 4 quarters since.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.